Dexcom G6 System CGM Real Time is now available to all consumers with type 1 diabetes covered by the Uninsured Health Benefits Program. | Aici


The content of the article

BURNABY, British Columbia – Dexcom, Inc. (NASDAQ: DXCM), the world leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage of the Dexcom G6 rtCGM System by the National Insurance Institute for Health Benefits (NIHB) The program has been expanded to include all clients with type 1 diabetes. This announcement expands the coverage already established for clients 2 to 19 years of age for more intensive insulin treatment, providing more to the Nation First and the Inuit access to this standard of care, which may help them to have more control over chronic diseases throughout their lives.

The content of the article

“Indigenous, First Nations and Inuit communities are affected by diabetes beyond childhood and adolescence, making this announcement an important step forward in ensuring better glucose control, improving health outcomes and reduce the risk of diabetes-related complications,” said Dr. Jeff Winterstein. , an internal medicine specialist in Edmonton who works with many NIHB patients who live with diabetes. “Additionally, CGM can help bridge the gap between remote communities and care providers. Dexcom CLARITY software allows me to remotely see patient glucose data and trends over time so I can make adjustments and make treatment decisions.

Using the Dexcom rtCGM has been proven to improve glycemic control1,2 and may reduce the risk of long-term complications associated with diabetes.3 As part of the NIHB coverage program, consumers 2 to 19 years of age on intensive insulin therapy AND consumers of all ages with type 1 diabetes can receive the Dexcom G6 rtCGM supply. directly from your local pharmacy.

“CGM has a positive impact on health1,2 for pediatric and adult patients and expanding access is an important step in creating a more integrated health care system across the country,” said Laura Endres, vice president of Dexcom. “We applaud the NIHB for empowering more people to take control of their health and live better lives with diabetes.”

Dexcom G6 uses a small, wearable sensor to continuously measure and transmit glucose levels to a smart device.* or receiver, providing real-time glucose data without having to constantly look or prick their finger. The system has customizable and predictive notifications and alerts to prevent dangerous low and high blood sugar events and a function that allows patients to share real-time glucose data with up to 10 followers.

The content of the article

Dexcom G6 also offers industry-leading connectivity through the integration of insulin delivery systems and digital health applications.

For more information about the Dexcom G6, please visit https://www.dexcom.com/en-CA/en-ca-dexcom-g6-cgm-system

To search the NIHB Drug Benefit List online for Dexcom G6 coverage details, visit https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407

About Dexcom, Inc.

Dexcom, Inc. is empowering people to control their diabetes with a new continuous glucose monitoring (CGM) system. Headquartered in San Diego, California in the United States, and operating in Canada, Dexcom has emerged as a technology leader in diabetes care. By listening to the needs of users, caregivers and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

If your glucose alerts and readings from the G6 don’t match your symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* For a list of compatible devices, please visit dexcom.com/compatibility

References

1 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
2 Welsh JB, Gao P, Derdzinski M, et al. A comparison of the accuracy, usability, and effectiveness of different continuous glucose monitoring systems. Diabetes Technol Ther 2019;21(3):128-32.
3 Roze S, Isitt J, Smith-Palmer J, Lynch P. Long-Term Cost-Effectiveness Evaluation of the Dexcom G6 Continuous Glucose Monitor Versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. Poster presentation presented at: 2020 Canadian Association for Population Therapeutics; October 27, 2020.

See the source version at businesswire.com: https://www.businesswire.com/news/home/20230117005450/en/

sign

Communication

Alena Atkinson, 705.206.9991
Veritas Communications
atkinson@veritasinc.com

#distro



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *